drugset / Trial / NCT03211234
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.
Timeline
- Start
- 2017-07-05
- Primary completion
- 2019-12-31
- Completion
- 2020-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 2 mg | Other |
| Subject | Carotuximab | Monoclonal antibody | 4 mg | Other |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Other |